# A Pathophysiological Model of Parkinson’s Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated Oxidative Injury in Critical Pigmented Neuronal Niches

**Authors:** Emilio Fernández-Espejo, Fernando Rodríguez de Fonseca

PMC · DOI: 10.3390/antiox15020201 · Antioxidants · 2026-02-03

## TL;DR

This paper proposes a new model for Parkinson’s disease, linking it to blood flow issues and immune cell activity in specific brain regions with pigmented neurons.

## Contribution

The novel hypothesis connects microvascular flow disturbance and immune-mediated oxidative injury to the onset of Parkinson’s disease pathology.

## Key findings

- Blood flow disturbance in pigmented neuronal niches may trigger immune cell activation and oxidative injury.
- Oxidative stress from immune cells could lead to accumulation of neuromelanin, lipofuscin, and alpha-synuclein.
- This mechanism may explain the spread of neurotoxic alpha-synuclein and progressive degeneration in Parkinson’s disease.

## Abstract

The authors hypothesize that idiopathic Parkinson’s disease may result from an alteration in microvascular flow at a “critical point” in the nervous system that is characterized by pigmented cells that express neuromelanin and/or lipofuscin. “Critical points” include the olfactory epithelium/bulb, the autonomic nervous system, the enteric nervous system, the prefrontal–cortico-pontine network, and the amygdala. Hypoxia–ischemia following blood flow disturbance would recruit and activate leukocytes and induce the infiltration of peripheral immune cells into neural tissue. The excess of toxic factors produced by hyperactive immune cells, such as myeloperoxidase and its derivatives, would cause the oxidation of lipids, proteins, and biogenic monoamines such as dopamine, which in turn would facilitate the accumulation and precipitation of neuromelanin, lipofuscin, and alpha-synuclein. In addition, neuromelanin and lipofuscin precipitates may accentuate the misfolding and aggregation of alpha-synuclein. This “amplification” mechanism could help explain the crucial role of pigmented neurons in the onset of Parkinson’s disease pathology, triggering abnormal neurotoxic alpha-synuclein spread throughout the nervous system from the “critical point” of origin, and enabling a self-perpetuating degenerative process. The proposed hypothesis may have implications for the identification of new therapeutic targets, early prevention strategies, and the development of vascular and/or immune biomarkers.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** FAM171A2 (family with sequence similarity 171 member A2) [NCBI Gene 284069], RPS12 (ribosomal protein S12) [NCBI Gene 6206] {aka S12, eS12}, GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629] {aka GBA, GCB, GLUC}, MED12L (mediator complex subunit 12L) [NCBI Gene 116931] {aka NIZIDS, NOPAR, TNRC11L, TRALP, TRALPUSH}, CLCN3 (Cl-/H+ antiporter 3) [NCBI Gene 1182] {aka CLC3, ClC-3, NEDHYBA, NEDSBA}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, FYN (FYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2534] {aka SLK, SYN, p59-FYN}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, Angpt1 (angiopoietin 1) [NCBI Gene 11600] {aka 1110046O21Rik, Ang-1, Ang1}, GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase) [NCBI Gene 10020] {aka DMRV, GLCNE, IBM2, NM, THC12, Uae1}, MPO (myeloperoxidase) [NCBI Gene 4353], NOD2 (nucleotide binding oligomerization domain containing 2) [NCBI Gene 64127] {aka ACUG, BLAU, BLAUS, CARD15, CD, CLR16.3}, LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892] {aka AURA17, DARDARIN, PARK8, RIPK7, ROCO2}, CYRIB (CYFIP related Rac1 interactor B) [NCBI Gene 51571] {aka BM-009, CYRI, CYRI-B, FAM49B, L1}, GBF1 (golgi brefeldin A resistant guanine nucleotide exchange factor 1) [NCBI Gene 8729] {aka ARF1GEF, CMT2GG, CMTDI2, CMTDIA}, FCGR2A (Fc gamma receptor IIa) [NCBI Gene 2212] {aka CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1}
- **Diseases:** DMC (MESH:C535726), multi-infarct vascular dementia (MESH:D015161), degenerative diseases (MESH:D019636), injury to (MESH:D014947), inflammation (MESH:D007249), Idiopathic Parkinson's disease (MESH:D010300), mitochondrial dysfunction (MESH:D028361), sleep disturbances (MESH:D012893), cerebral ischemia (MESH:D002545), microangiopathies (MESH:D014652), neurotoxic (MESH:D020258), neurocutaneous melanosis (MESH:C537387), Dementia with Lewy Bodies (MESH:D020961), alpha-synucleinopathies (MESH:D000080874), atrophy (MESH:D001284), anxiety (MESH:D001007), neuroinflammation (MESH:D000090862), BBB (MESH:C536830), lysosomal dysfunction (MESH:D016464), hemorrhagic (MESH:D006470), matter (MESH:D056784), strokes (MESH:D020521), functional disability (MESH:D003291), multiple system atrophy (MESH:D019578), motor deficits (MESH:D009461), ischemia (MESH:D007511), cerebral small vessel disease (MESH:D059345), Hypoxia (MESH:D000860), microvascular abnormalities (MESH:D017566), vascular dementia (MESH:D015140), pontine (MESH:D020295), age- (MESH:D019588), vascular dysfunction (MESH:D002561), Toxic (MESH:D064420), infarcts (MESH:D007238), depression (MESH:D003866), enteric (MESH:D004751), axonal degeneration (MESH:D009410), Parkinsonism (MESH:D010302), Lewy pathology (MESH:D005598), REM sleep behavior disorder (MESH:D020187), lacunar infarcts (MESH:D059409), cognitive impairment (MESH:D003072), dopaminergic (MESH:D009422)
- **Chemicals:** ibuprofen (MESH:D007052), AZD3241 (MESH:C000602652), 3,4-dihydroxyphenylacetic acid (MESH:D015102), Hypochlorite (MESH:D006997), aspirin (MESH:D001241), iron (MESH:D007501), Lipofuscin (MESH:D008062), C16 (-), reactive nitrogen species (MESH:D026361), Catecholamines (MESH:D002395), Nilotinib (MESH:C498826), levodopa/carbidopa (MESH:C009265), celecoxib (MESH:D000068579), amines (MESH:D000588), NM (MESH:C014121), melanin (MESH:D008543), lipid (MESH:D008055), dopamine (MESH:D004298), ROS (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A53T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938327/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938327/full.md

## References

151 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938327/full.md

---
Source: https://tomesphere.com/paper/PMC12938327